Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Cancer. 2016 May 15;122(10):1588-97. doi: 10.1002/cncr.29951. Epub 2016 Mar 11.
During the process of tumor profiling, there is the potential to detect germline variants. To the authors' knowledge, there currently is no accepted standard of care for how to deal with these incidental findings. The goal of the current study was to assess disclosure preferences among patients with cancer regarding incidental genomic variants that may be discovered during tumor profiling.
A 45-item questionnaire was administered to 413 patients in ambulatory oncology clinics. The survey captured demographic and disease variables and personal and family history, and presented case scenarios for different types of incidental germline variants that could theoretically be detected during genomic analysis of a patient's tumor.
The possibility of discovering non-cancer-related, germline variants did not deter patients from tumor profiling: 77% wanted to be informed concerning variants that could increase their risk of a serious but preventable illness, 56% wanted to know about variants that cause a serious but unpreventable illness, and 49% wanted to know about variants of uncertain significance. The majority of patients (75%) indicated they would share hereditary information regarding predisposition to preventable diseases with family and 62% would share information concerning unpreventable diseases. The most frequent concerns about incidental findings were ability to obtain health (48%) or life (41%) insurance. Only 21% of patients were concerned about privacy of information.
Patients with cancer appear to prefer to receive information regarding incidental germline variants, but there is substantial variability with regard to what information patients wish to learn. The authors recommend that personal preferences for the disclosure of different types of incidental findings be clarified before a tumor profiling test is ordered. Cancer 2016;122:1588-97. © 2016 American Cancer Society.
在肿瘤分析过程中,有可能检测到种系变异。据作者所知,目前尚无公认的标准来处理这些偶然发现。本研究的目的是评估癌症患者对在肿瘤分析过程中可能发现的偶然基因组变异的披露偏好。
在门诊肿瘤诊所对 413 名患者进行了 45 项问卷调查。该调查捕获了人口统计学和疾病变量以及个人和家族史,并提出了不同类型的偶然种系变异的病例情况,这些变异理论上可以在对患者肿瘤的基因组分析中检测到。
发现与癌症无关的种系变异并不会阻止患者进行肿瘤分析:77%的患者希望了解可能增加其患严重但可预防疾病风险的变异,56%的患者希望了解导致严重但不可预防疾病的变异,49%的患者希望了解意义不明的变异。大多数患者(75%)表示他们将与家人分享关于易患可预防疾病的遗传信息,62%的患者将分享有关不可预防疾病的信息。对偶然发现的最常见担忧是能否获得健康(48%)或人寿(41%)保险。只有 21%的患者担心信息隐私。
癌症患者似乎更愿意获得关于偶然种系变异的信息,但患者希望了解哪些信息存在很大的差异。作者建议在进行肿瘤分析测试之前,应明确患者对不同类型偶然发现的披露偏好。癌症 2016;122:1588-97。©2016 美国癌症协会。